NPP has been used therapeutically for several conditions including:
Breast cancer
Cachexia (wasting syndrome)
Osteoporosis
Anemias
Mechanism of Action
Nandrolone functions as an AR agonist by forming a receptor complex that facilitates nuclear translocation and subsequent direct binding to specific nucleotide sequences within chromosomal DNA.
Comparison with Nandrolone Decanoate (Deca)
NPP was the first nandrolone ester introduced, followed by nandrolone decanoate (Deca-Durabolin) in 1962. The key differences are:
Ester chain length: NPP has a shorter ester chain (phenylpropionate) compared to Deca’s longer decanoate ester
Absorption time: NPP takes 3-5 days to be fully absorbed by the bloodstream, while Deca takes 1-2 weeks
Onset of effects: NPP has a relatively fast onset compared to Deca
Water retention: NPP typically causes less water retention and bloating than Deca
In recent times, NPP has been largely superseded by nandrolone decanoate, which is longer-acting and more convenient to use.
Side Effects
Adverse effects associated with nandrolone esters include manifestations of masculinization such as acne, increased hair growth, alterations in vocal characteristics, and reduced libido, arising from their capacity to inhibit endogenous testosterone biosynthesis.
Nandrolone phenylpropionate (also called nandrolone phenpropionate) is an androgenic and anabolic steroid (AAS) that acts as an androgen receptor (AR) agonist
. It was approved by the FDA on October 30, 1959, under the trade name Durabolin for therapeutic intervention in breast cancer.
Reviews
There are no reviews yet.